Innerstream - wikimedia.orgRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Tag Archive for: Phase II
Armed Forces Institute of Pathology, AFIPFrench-Austrian vaccine maker Valneva SE has secured exclusive worldwide rights to commercialise LimmaTech Biologics AG’s S4V Shigella vaccine that will be tested in two Phase II trials starting in H2/2024.